We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $191M
1-Year Est. Return 102.42%
This Fund
S&P 500
This Quarter Est. Return
+35.53%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$172M
AUM Growth
+$18.2M
Cap. Flow
-$8.9M
Cap. Flow %
-5.16%
Top 10 Hldgs %
90.77%
Holding
27
New
3
Increased
3
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
ZVRA icon
Zevra Therapeutics
ZVRA
+$1.22M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$1.03M
3
ARDX icon
Ardelyx
ARDX
+$864K
4
CMPS
Compass Pathways
CMPS
+$564K
5
AKRO
Akero Therapeutics
AKRO
+$417K

Top Sells

Rank Stock Value
1
FULC icon
Fulcrum Therapeutics
FULC
+$4.65M
2
ABEO icon
Abeona Therapeutics
ABEO
+$3.26M
3
PAGP icon
Plains GP Holdings
PAGP
+$1.9M
4
KYN icon
Kayne Anderson Energy Infrastructure Fund
KYN
+$1.52M
5
TRVI icon
Trevi Therapeutics
TRVI
+$775K

Sector Composition

Rank Sector Weight
1 Healthcare 83.54%
2 Energy 13.65%
3 Technology 2.79%
4 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLT
1
DELISTED
Applied Therapeutics
APLT
$55.8M 32.38%
6,567,858
– –
PAGP icon
2
Plains GP Holdings
PAGP
$5.52B
$23.5M 13.65%
1,272,360
-100,000
-7% -$1.9M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$769M
$15.7M 9.12%
869,927
– –
ACHV icon
4
Achieve Life Sciences
ACHV
$874M
$11.6M 6.74%
2,453,092
– –
TCRX icon
5
TScan Therapeutics
TCRX
$26.5M
$10.4M 6.03%
2,087,139
– –
AKRO
6
DELISTED
Akero Therapeutics
AKRO
$9.86M 5.72%
343,729
+15,977
+5% +$417K
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.5B
$9.13M 5.3%
43,032
– –
RNAM
8
DELISTED
Avidity Biosciences
RNAM
$8.2M 4.76%
178,500
– –
ARDX icon
9
Ardelyx
ARDX
$976M
$7.38M 4.28%
1,070,947
+146,364
+16% +$864K
TSAT icon
10
Telesat
TSAT
$683M
$4.82M 2.79%
365,781
– –
ABEO icon
11
Abeona Therapeutics
ABEO
$343M
$3.94M 2.29%
624,022
-624,022
-50% -$3.26M
KYMR icon
12
Kymera Therapeutics
KYMR
$9.76B
$2.67M 1.55%
56,359
– –
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.84B
$2.57M 1.49%
133,259
+50,000
+60% +$1.03M
KURA icon
14
Kura Oncology
KURA
$1.18B
$2.54M 1.47%
130,000
– –
ZVRA icon
15
Zevra Therapeutics
ZVRA
$736M
$1.25M 0.72%
+179,874
New +$1.22M
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.24M 0.72%
146,381
– –
LONA
17
LeonaBio Inc
LONA
$71.2M
$666K 0.39%
149,279
– –
CMPS
18
Compass Pathways
CMPS
$1.84B
$504K 0.29%
+80,000
New +$564K
VRCA icon
19
Verrica Pharmaceuticals
VRCA
$91M
$500K 0.29%
34,494
-8,000
-19% -$360K
HELP
20
Cybin Inc
HELP
$893M
– –
-22,368
Closed -$230K
FULC icon
21
Fulcrum Therapeutics
FULC
$294M
– –
-750,000
Closed -$4.65M
KYN icon
22
Kayne Anderson Energy Infrastructure Fund
KYN
$2.5B
– –
-147,033
Closed -$1.52M
TRVI icon
23
Trevi Therapeutics
TRVI
$2.46B
– –
-260,000
Closed -$775K

Similar funds

CFG
Capital Financial Group Greenwood Village, Colorado $191M AUM
MWM
Magnolia Wealth Management Dothan, Alabama $191M AUM 17.58% 1-Year Est. Return
ALWM
Andrews Lucia Wealth Management Danville, California $191M AUM 24.94% 1-Year Est. Return
PFA
Pillar Financial Advisors Louisville, Kentucky $191M AUM 21.21% 1-Year Est. Return
LKWM
Lee-Kelleher Wealth Management Fulton, Maryland $191M AUM 28.48% 1-Year Est. Return
NWM
Navigoe Wealth Management Redondo Beach, California $191M AUM 25.21% 1-Year Est. Return
AA
Atmos Advisory Pittsburgh, Pennsylvania $191M AUM 12.84% 1-Year Est. Return
MCA
Martin Capital Advisors San Antonio, Texas $191M AUM 42.42% 1-Year Est. Return

Propel Bio Management's Q3 2024 Portfolio in Review

As of Q3 2024, Propel Bio Management held 27 positions worth $172M, up 12% from $154M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Propel Bio Management withdrew a net $8.9M in Q3 2024, closing 6 positions and reducing 3 holdings. Its most notable exit was Fulcrum Therapeutics, an estimated $4.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Energy and Technology.

Against the trend, Propel Bio Management opened a new position in Zevra Therapeutics worth $1.25M.

  • Propel Bio Management's largest Q3 2024 buy was Zevra Therapeutics: 179,874 shares worth $1.25M.
  • Propel Bio Management added most to Syndax Pharmaceuticals in Q3 2024, an estimated $1.03M increase.
  • Propel Bio Management's biggest Q3 2024 reduction was Abeona Therapeutics, cutting an estimated $3.26M.
  • Propel Bio Management fully exited Fulcrum Therapeutics in Q3 2024, selling an estimated $4.65M.
  • Propel Bio Management's ten largest holdings make up 91% of its $172M portfolio in Q3 2024.
  • Propel Bio Management opened 3 new positions and closed 6 in Q3 2024.
  • Propel Bio Management's portfolio value rose 12% quarter-over-quarter to $172M.

Based on Propel Bio Management's 13F filing for Q3 2024, filed 13 Nov 2024.